Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION A safety team sitting on a new disproportionate signal cannot treat a site-change that invalidates stability claims as incidental context on biosimilar analytical similarity report. CMC change-control owner must close to drop a secondary from that extract under Pharma & Life Sciences / Clinical and Evidence Strategy.

DECISION CMC change-control owner in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a site-change that invalidates stability claims.

HYPOTHESES TO TEST 1. The population in biosimilar analytical similarity report is the one a site-change that invalidates stability claims named, so Proceed under protocol follows for this Clinical and Evidence Strategy file. 2. The population in biosimilar analytical similarity report is adjacent only to a site-change that invalidates stability claims; Pause the pathway is the honest Pharma & Life Sciences call. 3. A safety team sitting on a new disproportionate signal already contained a site-change that invalidates stability claims before biosimilar analytical similarity report arrived; no new Clinical and Evidence Strategy path. 4. Provenance on biosimilar analytical similarity report after a site-change that invalidates stability claims is broken; do not pick Proceed under protocol or Pause the pathway yet.

ANALYSIS REQUIRED 1. Trace CMC, labeling, or pharmacovigilance facts in biosimilar analytical similarity report after a site-change that invalidates stability claims. 2. Separate an isolated adverse event from a systemic quality issue. 3. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read biosimilar analytical similarity report against a site-change that invalidates stability claims and write the one fact that would move to drop a secondary for CMC change-control owner.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (biosimilar analytical similarity report after a site-change that invalidates stability claims). The follow-on Clinical and Evidence Strategy action is what CMC change-control owner does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in biosimilar analytical similarity report, then the action for CMC change-control owner - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Clinical and Evidence Strategy finding in biosimilar analytical similarity report that a second reviewer can re-perform - Missing page in biosimilar analytical similarity report after a site-change that invalidates stability claims, if any